Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Chief Technology Officer | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.29 · Expires 2036-02-24 | Direct | 39,012 |
Reported balance
After 2026-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-24 · Grant · Acquired 39,012 · Balance 39,012 F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.86 · Expires 2036-02-24 | Direct | 39,011 |
Reported balance
After 2026-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-24 · Grant · Acquired 39,011 · Balance 39,011 F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
F2: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 26, 2026 07:02 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,011 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001999371-26-004386 · fogarty-form4_022626.xml · derivative · entry 2 Fogarty Siobhan · CIK 0002055825 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,011 Underlying: Common Stock · 39,011 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 07:02 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,012 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0001999371-26-004386 · fogarty-form4_022626.xml · derivative · entry 1 Fogarty Siobhan · CIK 0002055825 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,012 Underlying: Common Stock · 39,012 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:42 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 13,500 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001839882-25-011945 · fogarty-form4_022725.xml · derivative · entry 2 Fogarty Siobhan · CIK 0002055825 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-02-25 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:42 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 13,500 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001839882-25-011945 · fogarty-form4_022725.xml · derivative · entry 1 Fogarty Siobhan · CIK 0002055825 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-02-25 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.